Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

The lawsuit, which was filed in U.S. District Court in New Jersey by a single investor, Eric Barta, is a class action on ...

Novo Nordisk turns to insider to be next CEO after warning on both Ozempic and Wegovy sales Shares of Novo Nordisk had their worst single day since the Black Monday ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.